Market Research Logo

Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

INTRODUCTION
Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages. It is worth mentioning that the research and development efforts associated with antibody-based therapeutics have significantly paced up in 2017; this momentum is projected to continue over the coming several years. In fact, in 2017, more than 10 monoclonal antibodies were approved by the FDA and EMA. Additionally, close to 20 monoclonal antibodies are currently being evaluated in late stages of clinical development. In addition to monoclonal antibodies, other novel antibody-based therapeutics, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, are steadily gaining traction.

The discovery of antibodies is a long, arduous and cost intensive process. As a result, many biopharmaceutical developers are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery services, claim to have novel and advanced technologies to support players developing antibody-based products in their early stage research requirements. Additionally, there are a number of companies that have developed proprietary antibody discovery platforms and have made them available to drug developers. In-licensing the technology of such players for use in drug discovery operations is considered a viable business strategy, offering both time and cost related benefits to drug / therapy developers. As the demand for such therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to grow in the foreseen future.

SCOPE OF THE REPORT
The ‘Antibody Discovery: Services and Platforms (2nd Edition), 2018-2028’ report provides an extensive study on the current market landscape and future outlook of companies offering antibody discovery services and platforms. Amongst various elements, the report includes:

A detailed assessment of the current market landscape of companies offering antibody drug discovery services, including information on their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization / and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others).

An in-depth analysis of antibody platform providers, featuring information on their geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), type of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others).

A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large sized companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

A comparative landscape of service providers, highlighting the most important companies within North America, Europe and Asia Pacific, based on number of discovery services offered, number of discovery methods available, number of subject specific agreements signed, the company’s experience and size of employee base.

An insightful 2X2 competitiveness analysis of various antibody discovery platforms (segregated into three peer groups, namely library based method, transgenic mice, single cell based method), highlighting popular products based on the library size of the platform, types of antibody discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).

Comprehensive profiles of antibody discovery service and platform providers, featuring information on the location of their headquarters, year of establishment, antibody discovery service / platform portfolio, recent developments and a comprehensive future outlook.

A case study on antibody humanization and affinity maturation, including an exemplary list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends related to this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.

An analysis of the partnerships that have been established in the recent past, covering research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements, merger / acquisitions and others forms of collaborations.

An analysis of investments received by the service and platform providers, featuring details of capital raised via seed financing, venture capital financing, IPOs, debt financing and grants / awards, by companies that are operating within this domain.

A discussion on the upcoming opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided insights on the likely evolution of the market in different regions, including North America, Europe, China and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), and the nature of antibody generated (chimeric, humanized and fully human). In addition, we have estimated the future opportunity for platform providers in term of the likely licensing deal structures and the agreements that are expected to be signed in the foreseen future. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

Aaron Sato (Chief Scientific Officer, LakePharma)
Christel Iffland (Vice President, Ligand Pharmaceuticals)
Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
Debra Valsamis (Business Development Associate, Antibody Solutions)
Garren Hilow (Co-Founder and Chief Executive Officer, Abveris)
Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
Ignacio Pino (President and Chief Executive Officer, CDI Laboratories)
Jeng Her (Chief Executive Officer, AP Biosciences)
Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita)
Sanjiban K Banerjee (Director, AbGenics Life Sciences)
Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS

1. During our research, we identified over 70 players that are actively involved in providing antibody discovery services. It is worth highlighting that over 10 companies claim to be capable of offering services across all the steps of the antibody discovery process (antigen designing, hit generation, lead selection and, lead optimization and characterization services). These are (in alphabetical order) Aragen Bioscience, AvantGen, G&P Biosciences, Integral Molecular, IONTAS, LakePharma, WuXi AppTec, Creative BioStructure, Sino Biological, AP Biosciences and ModiQuest Research (acquired by ImmunoPrecise Antibodies).

2. Majority of the companies (39) use library-based methods for antibody discovery. Other methods that are being used include (in decreasing order of number of companies), hybridoma method (29), transgenic animal-based methods (16) and single cell-based methods (15).

3. Several companies have developed proprietary drug discovery platforms, and are monetizing their efforts by actively out-licensing them to drug developers, CROs and academic institutes. During the course of our study, we identified more than 40 such players. Of these, around 49% are headquartered in North America; examples include (in alphabetical order, no selection criteria) AbCellera, Ablexis, Ligand Pharmaceuticals, Single Cell Technology and TRIANNI. On the other hand, close to 40% of such companies are based in Europe, while the remaining operate out of the Asia Pacific region and rest of the world. Examples of platform providers based in the Europe and Asia Pacific include (in alphabetical order, no selection criteria) AIMM Therapeutics, ACYTE Biotech, BioInvent, Genmab, Harbour BioMed, Heptares Therapeutics, Isogenica, Kymab, Neurimmune and MOLCURE.

4. Over 300 strategic partnerships were forged between drug developers and CROs and / or technology providers during the period 2011-2018. It is worth mentioning that most of these partnerships were research collaborations (31%); this is indicative of the extensive research activity focused on discovering novel antibodies-based product candidates. Technology licensing and product development agreements were the second most popular partnership model, each representing 29% of the total number of deals. Prominent contract services and platform providers that have entered into multiple partnerships include (in alphabetical order) Adimab, Ligand Pharmaceuticals, TRIANNI, Genmab, AbCellera, Crystal Bioscience, MAB Discovery, AbCellera and Isogenica.

5. Over USD 2.6 billion, across 101 funding instances, has been invested in this market. Since 2009, we came across several grants, venture capital funding rounds and public offerings through which capital has been invested in companies in this market. Examples of players that have managed to secure significant capital investments in the period between 2009 and 2018 include (in alphabetical order) argenx, Akeso Biopharma, Kymab, Neurimmune, Sorrento Therapeutics and Zebra Biologics. Further, Bill & Melinda Gates Foundation, OrbiMed Advisors, Google Ventures, Legend Star Capital, Polaris Venture Partners, SV Life Sciences and Wellcome Trust emerged as prominent investors, in terms of their participation in the maximum number of funding instances in the given time period.

6. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to be worth over USD 2 billion in 2018 and steadily rise in the coming years. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate as compared to the established methods such as phage display and hybridoma methods.

7. The major share (over 80%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at faster rate (CAGR of 8.8%) as compared to other regions over the coming decade; this is attributed to the availability of skilled manpower, lower labor costs and a less stringent regulatory environment.

8. The sustained growth is also expected to result in lucrative monetizing opportunities for platform providers as they compete for a share within the USD 3 billion licensing deal revenues over the coming decade (in the form of upfront and milestone payments).

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.

Chapter 3 provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, namely, monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features information on the antibody discovery process and the various methods used in the discovery of such therapeutic biomolecules. It also includes a comparison of the different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 includes a comprehensive market landscape analysis of companies that offer antibody discovery services and / or have proprietary discovery platforms. For antibody discovery service providers, the chapter presents detailed analyses on the basis of their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others). For antibody discovery platform providers, the chapter includes analyses based on geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), types of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others). Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.

Chapter 6 presents a benchmark analysis of all the service providers engaged in this domain. It highlights the capabilities of the various companies in terms of their expertise across antibody discovery, enabling players to compare their existing capabilities within and beyond their respective peer groups and to identify opportunities to become more competitive in the industry.

Chapter 7 provides a comparative landscape of the service providers based on various parameters, such as the number of antibody discovery services offered, number of methods used for the discovery of antibodies, number of collaborations established in the recent past specifically focusing on the discovery and generation of antibodies, company size and experience. Based on the aforementioned analysis, the chapter highlights the most active players within North America, Europe and Asia-Pacific, in a 2X2 matrix.

Chapter 8 provides detailed profiles of some of the important players, based in different geographies, which are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information (if available), details on antibody discovery services and novel antibody discovery technology / platforms, and a comprehensive future outlook.

Chapter 9 features a comprehensive 2X2 analysis offering a comparative summary of all the technology platforms that we came across during our research. The analysis compares the aforementioned platforms within four groups [A] library-based technologies [B] transgenic mice-based technology platforms, [C] single cell-based technologies and [D] others. The platforms were compared based on the library size of the platform, types of antibodies discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).

Chapter 10 provides detailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information (if available), details on antibody discovery technology / platforms and a comprehensive future outlook.

Chapter 11 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements and merger / acquisitions) and the most common forms of deals / agreements that have been established in the period between 2011 to 2018.

Chapter 12 presents details on various investments received by the companies that are engaged in this domain. It also includes a detailed analysis of the funding instances that have taken place in the period January 2009 to May 2018, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the antibody discovery services domain till the year 2028. It features the likely distribution of the upcoming opportunity across [A] key geographies, namely North America, Europe (Germany, Switzerland, UK, France, Belgium and the rest of the Europe), Asia Pacific and rest of the world, [B] steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [C] antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and [D] the nature of antibody generated (murine, chimeric, humanized and fully human). In addition, we have provided a view on the likely upfront and milestone payments to be made in the licensing deals signed or planned with the focus on antibody discovery.

Chapter 14 provides detailed profiles on the top five therapeutic antibody products, which have generated the highest sales till 2017. Each profile covers information on the drug overview, historical sales, and discovery process and methods. The chapter provides information on Humira®, Rituxan®, Herceptin®, Remicade® and Avastin®.

Chapter 15 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents an exemplary list of key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models used by the players involved in this domain. In addition, chapter presents a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 16 provides an overview of future growth opportunities associated with the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have a notable influence on the industry’s evolution over the coming decade.

Chapter 17 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in providing antibody discovery services and platforms. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 18 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Aaron Sato (Chief Scientific Officer, LakePharma), Christel Iffland (Vice President, Ligand Pharmaceuticals), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Debra Valsamis (Business Development Associate, Antibody Solutions), Garren Hilow (Co-Founder and Chief Executive Officer, Abveris), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita), Sanjiban K Banerjee (Director, AbGenics Life Sciences), , and Thomas Schirrmann (CEO and General Manager, YUMAB).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report:
1. 4-Antibody
2. A*STAR's Genome Institute of Singapore
3. AB Biosciences
4. Ab Studio
5. ABBA Therapeutics
6. AbBioSci
7. AbbVie
8. AbCellera
9. AbCheck
10. Abeome
11. AbGenics Life Sciences
12. Abgent
13. Ablexis
14. Abpro
15. Absolute Antibody
16. Abwiz Bio
17. Abzena
18. Abzyme Therapeutics
19. Accel
20. Acceleron Pharma
21. Accurus Biosciences
22. Achaogen
23. ACROBiosystems
24. ACYTE Biotech
25. Adagene
26. Adimab
27. Aduro Biotech
28. Advantech Capital
29. Agenus
30. AIMM Therapeutics
31. Aitua
32. Akeagen
33. Alder BioPharmaceuticals
34. Alector
35. Alere
36. Alexandria Real Estate Equities
37. Alexion Pharmaceuticals
38. Ally Bridge Group
39. Amdec Group
40. Amgen
41. Ampersand Capital Partners
42. AnaptysBio
43. AP Biosciences
44. Apexigen
45. Aquila Capital
46. Aragen Bioscience
47. ARCH Venture Partners
48. argenx
49. Aridis Pharmaceuticals
50. Aristi Biotech
51. Astellas Venture Management
52. AstraZeneca
53. Atlas Venture
54. Atreca
55. AvantGen
56. Avlar BioVentures
57. AxioMx
58. Ballast Point Ventures
59. Bayer
60. BASF
61. BBI Group
62. BeiGene
63. Beijing Shijilongxin Investment
64. Berkeley Lights
65. Bill & Melinda Gates Foundation
66. BioAtla
67. Biogen
68. BioGeneration Ventures
69. BioInvent International
70. BioLauncher
71. Biomirex
72. BioNTech
73. Bio-Rad
74. BioRap Technologies
75. Biosin
76. BIOTEM
77. Birchmere Labs
78. Bird Rock Bio
79. Blue Sky BioServices
80. bluebird bio
81. Boehringer Ingelheim
82. Borealis Ventures
83. Bristol-Myers Squibb
84. Brigham and Women's Hospital
85. Burrage Capital
86. BVF Partners
87. Canaan Partners
88. Cambridge Antibody Technology
89. Capra Science Antibodies
90. Case Western Reserve University School of Medicine
91. Catalent Biologics
92. Celexion
93. Celgene
94. Cellectis
95. Celltrion
96. Centers for Disease Control and Prevention
97. ChemBio Discovery Solutions
98. ChemPartner
99. Chiome Bioscience
100. Chugai Pharmaceutical
101. Chugai Pharmabody Research
102. Cisbio
103. CNA Development
104. Compass Therapeutics
105. Compugen
106. Commission for Technology and Innovation
107. ContraFect
108. Corixa
109. Cormorant Pharmaceuticals
110. Cosmo Pharmaceuticals
111. Creative Biolabs
112. Crescendo Biologics
113. Cresset Biomolecular Discovery
114. Crucell
115. Crystal Bioscience
116. Cullinan Oncology
117. Cytogen
118. DAFNA Capital Management
119. Daiichi Sankyo
120. Dako
121. Dana-Farber Cancer Institute
122. DaTaMabs
123. Defense Threat Reduction Agency
124. Department of Health and Human Services
125. Digital Proteomics
126. Distributed Bio
127. DJS Antibodies
128. Dyax
129. Effimune
130. Elan
131. Eli Lilly
132. Elusys Therapeutics
133. EMBL Ventures
134. Emergent BioSolutions
135. Emory University
136. Enthera
137. Enumeral
138. EpiCypher
139. EpimAb Biotherapeutics
140. Erasmus MC Biomedical Fund
141. Essex Bio-Technology
142. Eureka Therapeutics
143. European Investment Bank
144. EVA Basel
145. Evotec
146. Exiris
147. FairJourney Biologics
148. Ferring Pharmaceuticals
149. Five Prime Therapeutics
150. Flanders Innovation and Entrepreneurship
151. Floodgate Fund
152. Forbion Capital Partners
153. Fred Hutchinson Cancer Research Center
154. Fresenius
155. F-star
156. Fusion Antibodies
157. G&P Biosciences
158. Genedata
159. GeneBeyond
160. GeneFrontier
161. Genentech
162. Genetix
163. Genmab
164. Genor Biopharma
165. GenScript
166. Genzyme
167. Georgia Institute of Technology
168. GigaGen
169. Gilead Sciences
170. GlaxoSmithKline
171. Glenmark Pharmaceuticals
172. GlycoNex
173. Grenoble Hospital
174. GTJA Investment Group
175. GVK Biosciences
176. Harbour BioMed
177. Harpoon Therapeutics
178. HD Biosciences
179. HealthCare Ventures
180. Henlix Biotech
181. Heptares Therapeutics
182. Hercules Capital
183. HitGen
184. HQL Pharmaceuticals
185. Humabs BioMed
186. Human Genome Sciences
187. IBC Generium
188. Ibex Biosciences
189. IGEM Therapeutics
190. Igenica Biotherapeutics
191. ImClone Systems
192. Immune Biosolutions
193. Immunex
194. ImmunoChina Pharmaceuticals
195. Immunologix
196. Immunome
197. Immunomedics
198. Immunomic Therapeutics
199. ImmunoPrecise Antibodies
200. Imperial Innovations
201. In-Cell-Art
202. Innovate UK
203. Innovative Targeting Solutions
204. Innovent Biologics
205. Institut Pasteur
206. Institute for the Promotion of Innovation by Science and Technology
207. Integral Molecular
208. Intrexon
209. Invenra
210. IONTAS
211. Isogenica
212. iTeos Therapeutics
213. Janssen Biotech
214. Jazz Pharmaceuticals
215. Jiangsu Hengrui Medicine
216. Johnson & Johnson
217. Jounce Therapeutics
218. Juno Therapeutics
219. Kaken Pharmaceutical
220. KBC Private Equity
221. KindredBio
222. King Star
223. Kite Pharma
224. Kodiak Sciences
225. Kymab
226. Kyowa Hakko Kirin
227. LakePharma
228. Leland Stanford Junior University
229. LEO Pharma
230. Les Laboratoires Servier
231. Life Sciences Partners
232. Ligand Pharmaceuticals
233. Lilly Asia Ventures
234. LYFE Capital
235. MAB Discovery
236. MabPlex
237. MabSpace Biosciences
238. MabVax Therapeutics
239. MacroGenics
240. Magenta Therapeutics
241. Malin
242. Massachusetts General Hospital
243. MassBiologics
244. Maverick Therapeutics
245. MD Anderson Cancer Center
246. Medarex
247. Medical Research Council
248. MediMabs
249. MedImmune
250. Meditope Biosciences
251. MEMO Therapeutics
252. Memorial Sloan Kettering Cancer Center
253. Merck
254. Mersana Therapeutics
255. Merus
256. MidCap Financial
257. Millennium Pharmaceuticals
258. Mitsubishi Tanabe Pharma
259. ModiQuest Research
260. Molcure
261. Molecular Devices
262. Molecular Templates
263. Moradec
264. MorphoSys
265. MPM Capital
266. MSM Protein Technologies
267. National Institute of Allergy and Infectious Diseases
268. National Institutes of Health
269. NB Health Laboratory
270. NBE Therapeutics
271. NeoClone
272. Nest.Bio Ventures
273. Neurimmune
274. NGM Biopharmaceuticals
275. North Coast Biologics
276. NovaRock Biotherapeutics
277. Novartis
278. Novimmune
279. Novo Nordisk
280. Numab
281. NXT Ventures
282. Oak BioSciences
283. Olympic Protein Technologies
284. Omnes Capital
285. OncoMed Pharmaceuticals
286. Oncobiologics
287. Oncothyreon
288. Ono Pharmaceutical
289. Open Monoclonal Technology
290. OrbiMed Advisors
291. Organon Teknika
292. ORI Healthcare Fund
293. OriMAbs
294. Ossianix
295. Oxford BioTherapeutics
296. Ozyme
297. Palatin Technologies
298. Pfizer
299. PharmAthene
300. Phylogica
301. Pierre Fabre
302. Polaris Partners
303. Porton Pharma Solutions
304. Potenza Therapeutics
305. Prime Value Capital Management
306. ProteoGenix
307. Proxima Ventures
308. Pure Biologics
309. PX'Therapeutics
310. Qianhai Fund of Funds
311. Qiming Venture Partners
312. QoolAbs
313. Quanta BioDesign
314. Queen Mary University of London
315. RayBiotech
316. Redalpine Venture Partners
317. Regeneron Pharmaceuticals
318. Research Corporation Technologies
319. ResearchPoint Global
320. ribOvax Biotechnologies
321. Roche
322. Rx Biosciences
323. SAB Biotherapeutics
324. Sanofi
325. Scripps Research Institute
326. Sea Lane Biotechnologies
327. Seattle Genetics
328. Selexis
329. Sequoia Capital
330. Sevion Therapeutics
331. Shanghai Jianxin Capital
332. ShangPharma Innovation
333. Shenogen Pharma
334. Shenzhen Capital Group
335. Shenzhen Hepalink Pharmaceutical
336. Shenzhen Innovation Investment Group
337. Shenzhen Xinnuo Health Industry Investment
338. Shire
339. Siamab Therapeutics
340. Silicon Valley Bank
341. Silverton Partners
342. Singapore Immunology Network
343. Single Cell Technology
344. Sino Biological
345. Soligenix
346. Sorrento Therapeutics
347. SOTIO
348. Specifica
349. Spectrum Pharmaceuticals
350. Sphere Fluidics
351. Stanford University
352. Sucampo Pharmaceuticals
353. Surface Oncology
354. Sutro Biopharma
355. SV Life Sciences
356. Swedish Orphan Biovitrum
357. Symphogen
358. Synthetic Biologics
359. Synthon Biopharmaceuticals
360. Takeda Pharmaceutical
361. Tanabe Research Laboratories
362. TeneoBio
363. TetraGenetics
364. Teva Pharmaceutical
365. The French National Institute of Health and Medical Research
366. Theraclone Sciences
367. Theranyx
368. Tizona Therapeutics
369. Torch Biosciences
370. Transgene
371. TransGenic
372. Trellis Bioscience
373. TRIANNI
374. Tri-Institutional Therapeutics Discovery Institute
375. TriWise Capital
376. Twist Bioscience
377. U3 Pharma
378. UCB
379. United Therapeutics
380. University of California
381. University of Southampton
382. University of Texas
383. University of Turku
384. Vaccinex
385. Valeant Pharmaceuticals
386. venBio
387. Versant Ventures
388. VI Ventures
389. Viva Biotech
390. Viventia Bio
391. Wellcome Trust Sanger Institute
392. Woodford Investment Management
393. WuXi AppTec
394. Wyeth
395. XBiotech
396. xCella Biosciences
397. XOMA
398. YUMAB
399. YuRoGen Biosystems
400. Zebra Biologics
401. ZENOAQ
402. Zurich Cantonal Bank
403. Zymeworks


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Discovery
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Applications of Antibodies
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In Vitro Display Methods
4.3.2.1. Phage Display Method
4.3.2.2. Yeast Display Method
4.3.2.3. Ribosomal Display Method
4.3.3. Transgenic Animals Based Method
4.3.4. Single B Cell Based Method
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies
4.5.1. Fully Human Monoclonal Antibodies
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: Overall Market Landscape
5.2.1. Analysis by Antibody Discovery Steps
5.2.2. Analysis by Antibody Generation Methods
5.2.3. Analysis by Purpose for Antibody Discovery
5.2.4. Analysis by Type of Antibodies Discovered
5.2.5. Analysis by Animal Model Used
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Analysis by Antibody Generation Methods
5.3.2. Analysis by Type of Antibodies Discovered
5.3.3. Analysis by Animal Model Used
5.3.4. Antibody Discovery Service and Platform Providers: Analysis by Geographical Location
5.4. Antibody Discovery Platform Providers: for In-house Purposes
6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.4. Benchmark Analysis: North America Based Companies
6.4.1. Peer Group I
6.4.2. Peer Group II
6.4.3. Peer Group III
6.5. Benchmark Analysis: Europe and Asia-Pacific Based Companies
6.5.1. Peer Group IV
6.5.2. Peer Group V
6.5.3. Peer Group VI
7. COMPARATIVE ANALYSIS OF SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: Competitive Landscape
7.3. Antibody Discovery Service Providers: Comparative Analysis by Region
7.3.1. Key Players in North America
7.3.2. Key Players in Europe
7.3.3. Key Players in Asia-Pacific
8. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
8.1. Chapter Overview
8.2. Antibody Discovery Service Providers in North America
8.2.1. Abwiz Bio
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Antibody Discovery Services
8.2.1.4. Antibody Discovery Platforms
8.2.1.4.1. Needle-in-a-Haystack Technology™
8.2.1.4.2. RabWiz™
8.2.1.4.3. WizAmp™
8.2.1.5. Recent Developments
8.2.1.5.1. Partnerships
8.2.1.6. Future Outlook
8.2.2. Aragen Bioscience (A GVK BIO Company)
8.2.2.1. Company Overview
8.2.2.2. Antibody Discovery Services
8.2.2.3. Recent Developments
8.2.2.3.1. Expansions
8.2.2.3.2. Partnerships
8.2.2.4. Future Outlook
8.2.3. Integral Molecular
8.2.3.1. Company Overview
8.2.3.2. Financial Information
8.2.3.3. Antibody Discovery Services
8.2.3.4. Recent Developments
8.2.3.5. Future Outlook
8.2.4. LakePharma
8.2.4.1. Company Overview
8.2.4.2. Antibody Discovery Services
8.2.4.3. Recent Developments
8.2.4.3.1. Expansions
8.2.4.3.2. Partnerships
8.2.4.4. Future Outlook
8.3. Antibody Discovery Service Providers in Europe
8.3.1. Abzena
8.3.1.1. Company Overview
8.3.1.2. Financial Information
8.3.1.3. Antibody Discovery Services
8.3.1.4. Recent Developments
8.3.1.4.1. Expansions
8.3.1.4.2. Partnerships
8.3.1.5. Future Outlook
8.3.2. MAB Discovery
8.3.2.1. Company Overview
8.3.2.2. Financial Information
8.3.2.3. Antibody Discovery Services
8.3.2.4. Recent Developments
8.3.2.5. Future Outlook
8.3.3. ModiQuest Research (Acquired by ImmunoPrecise Antibodies)
8.3.3.1. Company Overview
8.3.3.2. Antibody Discovery Services
8.3.3.3. Antibody Discovery Platforms
8.3.3.3.1. ModiVacc™
8.3.3.3.2. ModiFuse™: Proprietary Hybridoma Platform
8.3.3.3.3. ModiSelect™: Proprietary B Cell Selection Platform
8.3.3.3.4. ModiPhage™: In-House and Custom Phage Libraries
8.3.3.3.5. ModiTune™: Antibody Optimization Platform
8.3.3.3.6. ModiXpress™: Proprietary In-House Expression Platform
8.3.3.4. Recent Developments
8.3.3.4.1. Partnerships
8.3.3.5. Future Outlook
8.3.4. PX'Therapeutics (Acquired by Aguettant Pharmaceutical Group)
8.3.4.1. Company Overview
8.3.4.2. Antibody Discovery Services
8.3.4.3. Recent Developments
8.3.4.3.1. Partnerships
8.3.4.4. Future Outlook
8.4. Antibody Discovery Service Providers in Asia-Pacific
8.4.1. ChemPartner
8.4.1.1. Company Overview
8.4.1.2. Antibody Discovery Services
8.4.1.3. Recent Developments
8.4.1.3.1. Expansions
8.4.1.3.2. Partnerships
8.4.1.4. Future Outlook
8.4.2. Viva Biotech
8.4.2.1. Company Overview
8.4.2.2. Antibody Discovery Services
8.4.2.3. Recent Developments
8.4.2.3.1. Partnerships
8.4.2.4. Future Outlook
8.4.3. WuXi AppTec
8.4.3.1. Company Overview
8.4.3.2. Financial Information
8.4.3.3. Antibody Discovery Services
8.4.3.4. Recent Developments
8.4.3.4.1. Expansions
8.4.3.4.2. Partnerships
8.4.3.5. Future Outlook
9. COMPETITIVENESS ANALYSIS OF ANTIBODY DISCOVERY PLATFORMS
9.1. Chapter Overview
9.2. Library-Based Antibody Discovery Platforms
9.3. Transgenic Animal-Based Antibody Discovery Platforms
9.4. Single Cell-Based Antibody Discovery Platforms
9.5. Other Antibody Discovery Platforms
10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Antibody Discovery Platform Providers in North America
10.2.1. Invenra
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. Antibody Discovery Platforms
10.2.1.3.1. B-Body™ Platform
10.2.1.4. Recent Developments
10.2.1.5. Future Outlook
10.2.2. Ligand Pharmaceuticals
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. Antibody Discovery Platforms
10.2.2.3.1. OmniAb®
10.2.3.4. Patent Portfolio
10.2.2.5. Recent Developments
10.2.2.6. Future Outlook
10.2.3. Sorrento Pharmaceuticals
10.2.3.1. Company Overview
10.2.3.2. Financial Information
10.2.3.3. Antibody Discovery Platforms
10.2.3.3.1. G-MAB™ Technolog
10.2.3.5.
10.2.3.4. Future Outlook
10.2.4. Single Cell Technology
10.2.4.1. Company Overview
10.2.42. Financial Information
10.2.4.3. Antibody Discovery Platforms
10.2.4.3.1. AbTHENEUM™
10.2.4.4. Recent Developments
10.2.4.5. Future Outlook
10.2.5. TRIANNI
10.2.5.1. Company Overview
10.2.5.2. The Trianni Mouse™ Platform
10.2.5.3. Patent Portfolio
10.2.5.4. Recent Developments
10.2.5.5. Future Outlook
10.2.6
10.3. Antibody Discovery Platform Providers in Europe
10.3.1. AIMM Therapeutics
10.3.1.1. Company Overview
10.3.1.2. Financial Information
10.3.1.3. Antibody Discovery Platforms
10.3.1.3.1. AIMSelect Platform
10.3.1.4. Recent Developments
10.3.1.5. Future Outlook
10.3.2. BioInvent
10.3.2.1. Company Overview
10.3.2.2. Financial Information
10.3.2.3. Antibody Discovery Platforms
10.3.2.3.1. n-CoDeR® Antibody Library Platform
10.3.2.4. Recent Developments
10.3.2.5. Future Outlook
10.3.3. Genmab
10.3.3.1. Company Overview
10.3.3.2. Financial Information
10.3.3.3. Antibody Discovery Platforms
10.3.3.3.1. DuoBody® Technology
10.3.3.4. Recent Developments
10.3.3.5. Future Outlook
10.3.4. Kymab
10.3.4.1. Company Overview
10.3.4.2. Financial Information
10.3.4.3. Antibody Discovery Platforms
10.3.4.3.1. Kymouse™ Platform
10.3.4.4. Patent Portfolio
10.3.4.5. Recent Developments
10.3.4.6. Future Outlook
10.4. Antibody Discovery Platform Providers in Asia-Pacific
10.4.1. Harbour BioMed
10.4.1.1. Company Overview
10.4.1.2. Financial Information
10.4.1.3. Antibody Discovery Platforms
10.4.1.3.1. H2L2
10.4.1.3.2. HCAb
10.4.1.4. Patent Portfolio
10.4.1.5. Recent Developments
10.4.1.6. Future Outlook
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Antibody Discovery Service and Platform Providers: List of Partnerships and Collaborations
11.3.1. Analysis by Number of Partnerships
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Focus Area
11.3.4 Most Active Players: Analysis by Number of Partnerships
11.4.
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. Antibody Discovery Services and Platforms Market: Funding and Investment Analysis
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Most Active Players
12.3.5. Analysis by Most Active Investors
12.4. Concluding Remarks
13. OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology
13.3. Antibody Discovery Services Market, 2018-2028 (USD Billion)
13.4. Antibody Discovery Services Market, 2018-2028: Distribution by Regions (USD Billion)
13.4.1. Antibody Discovery Services Market: North America, 2018-2028 (USD Billion)
13.4.2. Antibody Discovery Services Market: Europe, 2018-2028(USD Billion)
13.4.3. Antibody Discovery Services Market: China, 2018-2028 (USD Billion)
13.4.4. Antibody Discovery Services Market: Rest of the World, 2018-2028 (USD Billion)
13.4.5. Market Attractiveness Analysis by Region
13.5. Antibody Discovery Services Market, 2018-2028: Distribution by Antibody Discovery Steps (USD Billion)
13.6. Antibody Discovery Services Market, 2018-2028: Distribution by Antibody Generation Methods (USD Billion)
13.6.1. Market Attractiveness Analysis by Antibody Generation Method
13.7. Antibody Discovery Services Market, 2018-2028: Distribution by Type of Antibody Generated (USD Billion)
13.8. Antibody Discovery Platforms Market, 2018-2030: Licensing Deals
13.8. 1. Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030
14. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
14.1. Chapter Overview
14.2. Humira® (Adalimumab)
14.2.1. Drug Overview
14.2.2. Discovery Process and Method
14.2.3. Historical Sales
14.3. Rituxan® (Rituximab)
14.3.1. Drug Overview
14.3.2. Discovery Process and Method
14.3.3. Historical Sales
14.4. Herceptin® (Trastuzumab)
14.4.1. Drug Overview
14.4.2. Discovery Process and Method
14.4.3. Historical Sales
14.5. Remicade® (Infliximab)
14.5.1. Drug Overview
14.5.2. Discovery Process and Method
14.5.3. Historical Sales
14.6. Avastin® (Bevacizumab)
14.6.1. Drug Overview
14.6.2. Discovery Process and Method
14.6.3. Historical Sales
15. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
15.1. Importance of Antibody Humanization and Affinity Maturation
15.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
15.3. Antibody Humanization: Publication Analysis
15.3.1. Publication Analysis: Year-Wise Trend
15.3.2. Publication Analysis: Key Journals
15.3.3. Publication Analysis: Distribution by Animal Model Used
15.3.4. Publication Analysis: Distribution by Method Used for Humanization
15.4. Antibody Humanization Service and Platform Providers: SWOT Analysis
16. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
16.1. Chapter Overview
16.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
16.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
16.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
16.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
16.6. Growing Market Opportunities in the Asia-Pacific Region
16.7. Expected Increase in Number of Collaboration and Licensing Activity
17. SURVEY INSIGHTS
17.1. Chapter Overview
17.2. Designation of Respondents
17.3. Antibody Discovery Stages
17.4. Antibody Generation Methods
17.5. Type of Antibody Discovered
17.6. Location of Antibody Discovery Facility / Laboratory
17.7. Likely Estimates of Current Market Size
18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Aaron Sato, Chief Scientific Officer, LakePharma
18.3. Christel Iffland, Vice President, Ligand Pharmaceuticals
18.4. Chun-Nan Chen, Chief Executive Officer & Chief Scientific Officer, Single Cell Technology
18.5. Debra Valsamis, Business Development Associate, Antibody Solutions
18.6. Garren Hilow, Co-Founder and Chief Executive Officer, Abveris
18.7. Giles Day, Co-Founder and Chief Executive Officer, Distributed Bio
18.8. Ignacio Pino, President and Chief Executive Officer, CDI Laboratories
18.9. Jeng Her, Chief Executive Officer, AP Biosciences
18.10. Kevin Heyries, Co-Founder and Lead of Business Development Strategy, AbCellera
18.11. Nalini Ghag- Motwani, President and Founding Chief Scientist, BioSavita
18.12. Sanjiban K Banerjee, Director, AbGenics Life Sciences
18.13. Thomas Schirrmann, Chief Executive Officer and General Manager, YUMAB
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibody Therapeutics
Figure 4.7 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1 Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
Figure 5.2 Antibody Discovery Services Providers: Antibody Discovery Methods
Figure 5.3 Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Figure 5.4 Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered
Figure 5.5 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.6 Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
Figure 5.7 Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered
Figure 5.8 Antibody Discovery Platform Providers: Distribution by Animal Model Used
Figure 5.9 Antibody Discovery Service and Platform Providers: Geographical Distribution
Figure 6.1 Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
Figure 6.2 Benchmark Analysis: North America Based Companies, Peer Group I
Figure 6.3 Benchmark Analysis: North America Based Companies, Peer Group II
Figure 6.4 Benchmark Analysis: North America Based Companies, Peer Group III
Figure 6.5 Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group IV
Figure 6.6 Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group V
Figure 6.7 Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group VI
Figure 7.1 Antibody Discovery Service Providers: Competitive Landscape in North America
Figure 7.2 Antibody Discovery Service Providers: Competitive Landscape in Europe
Figure 7.3 Antibody Discovery Service Providers: Competitive Landscape in Asia-Pacific
Figure 8.1 Abwiz Bio: Antibody Discovery Services
Figure 8.2 LakePharma: Antibody Discovery Services
Figure 8.3 Abzena: Antibody Discovery Services
Figure 8.4 ChemPartner: Antibody Discovery Services
Figure 9.1 Platform Competitiveness Analysis: Library Based Antibody Discovery Platforms
Figure 9.2 Platform Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 9.3 Platform Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
Figure 9.4 Platform Competitiveness Analysis: Other Platforms
Figure 10.1 Ligand Pharmaceuticals: Technology Portfolio
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2012- Q1 2018 (USD Million)
Figure 10.3 AIMM Therapeutics: Technology Platforms
Figure 10.4 Sorrento Therapeutics: Technology Platforms
Figure 10.5 Genmab: Technology Platforms
Figure 11.1 Distribution by Number of Collaborations
Figure 11.2 Distribution by Type of Partnership
Figure 11.3 Year-Wise Distribution by Type of Collaboration
Figure 11.4 Distribution by Type of Partnership Among Platform and Service Providers
Figure 11.5 Leading Players by Number of Partnerships
Figure 11.6 Key Focus Areas
Figure 11.7 Antibody Discovery Services and Platforms Collaborations: Novel Antibody Types (2017-2018)
Figure 12.1 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018
Figure 12.2 Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Amount Invested by Year, 2009-2018 (USD Million)
Figure 12.4 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Figure 12.5 Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018
Figure 12.6 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Figure 12.7 Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
Figure 12.8 Funding and Investment Analysis: Most Active Players
Figure 12.9 Funding and Investment Analysis: Most Active Investors
Figure 12.10 Funding and Investment Summary
Figure 13.1 Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
Figure 13.2 Antibody Discovery Services Market, 2018 and 2028: Distribution by Geography, Base Scenario (USD Billion)
Figure 13.3 Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
Figure 13.4 Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
Figure 13.5 Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion)
Figure 13.6 Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
Figure 13.7 Antibody Discovery Services: Market Attractiveness Analysis by Geography
Figure 13.8 Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Figure 13.9 Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 13.10 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 13.11 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 13.12 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Base Scenario (in Percentage)
Figure 13.13 Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated, Base Scenario (USD Billion)
Figure 13.13 Antibody Discovery Platforms Market, 2018-2030: Number of Licensing Deals 2018 and 2030
Figure 13.13 Antibody Discovery Platforms Market, 2018 2030: Upfront and Milestone Payments, 2018, 2025 and 2030
Figure 14.1 Humira®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.2 Rituxan®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.3 Herceptin®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.4 Remicade®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.5 Avastin®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.1 Publication Analysis: Quarterly Distribution
Figure 14.2 Publication Analysis: Distribution by Key Journals
Figure 14.3 Publication Analysis: Distribution by Study Model
Figure 14.4 Publication Analysis: Distribution by Method Used for Humanization
Figure 14.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 14.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 14.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 14.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 14.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 16.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 16.2 Number of Licensing Deals, 2011- 2017
Figure 17.1 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Figure 17.2 Survey Insights: Distribution by Designation and Seniority Level
Figure 17.3 Survey Insights: Distribution by Antibody Discovery Stages
Figure 17.4 Survey Insights: Distribution by Antibody Discovery Methods
Figure 17.5 Survey Insights: Distribution by Type of Antibody Discovered
Figure 17.6 Survey Insights: Distribution by Location of Antibody Discovery Facility / Laboratory
Figure 17.7 Survey Insights: Distribution by Likely Market Size
LIST OF TABLES
Table 3.1 Antibody Isotypes: Key Features
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Distribution by Antibody Discovery Steps
Table 5.3 Distribution by Antibody Discovery Methods
Table 5.4 Distribution by Purpose of Antibody Discovery
Table 5.5 Distribution by Type of Antibodies Discovered
Table 5.6 Distribution by Animal Model Used
Table 5.7 List of Antibody Discovery Platform Providers
Table 5.8 Distribution by Antibody Discovery Methods
Table 5.9 Distribution by Type of Antibodies Discovered
Table 5.10 Distribution by Animal Model Used
Table 5.11 Antibody Discovery Platforms used for In-house Purposes
Table 6.1 Benchmark Analysis: Peer Groups
Table 7.1 Antibody Discovery Service Providers: Qualitative Comparison of Key Parameters
Table 8.1 Abwiz Bio: Future Outlook
Table 8.3 Aragen Bioscience: Future Outlook
Table 8.4 Integral Molecular: Future Outlook
Table 8.5 LakePharma: Future Outlook
Table 8.6 Abzena: Future Outlook
Table 8.7 MAB Discovery: Future Outlook
Table 8.8 PX'Therapeutics: Future Outlook
Table 8.9 ChemPartner: Future Outlook
Table 8.10 Viva Biotech: Future Outlook
Table 8.11 WuXi AppTec: Future Outlook
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 Distributed Bio: Future Outlook
Table 10.2 Invenra: Future Outlook
Table 10.3 OmniAb® Technology: Key Features
Table 10.4 OmniAb® Technology: Patent Information
Table 10.5 OmniChicken® Technology: Patent Information
Table 10.6 Ligand Pharmaceuticals: Future Outlook
Table 10.7 Sorrento Therapeutics: Future Outlook
Table 10.8 The Trianni Mouse™: Key Features
Table 10.9 TRIANNI: Future Outlook
Table 10.10 Single Cell Technology: Future Outlook
Table 10.11 AIMSelect Platform: Key Features
Table 10.12 AIMM Therapeutics: Future Outlook
Table 10.13 BioInvent: Future Outlook
Table 10.14 Kymab: Funding Instances
Table 10.15 Kymouse™: Key Features
Table 10.16 Kymab: Future Outlook
Table 10.17 H2L2 Platform: Key Features
Table 10.18 HCAb Platform: Key Features
Table 10.19 Harbour BioMed: Future Outlook
Table 11.1 Antibody Discovery Services and Platforms: Partnerships and Collaborations, 2011-2018
Table 12.1 Antibody Discovery Service and Platform Providers Market: Funding and Investments, 2009-2018
Table 12.2 Funding and Investment Analysis: Summary of Investments
Table 14.1 Top Ten Selling Therapeutic Antibodies, 2017
Table 14.1 Approved Monoclonal Antibodies: Information on Affinity
Table 14.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 14.3 Antibody Humanization and Affinity Maturation: Description of Services and Platform Providers
Table 14.4 Antibody Humanization: Recent Publications
Table 14.5 Antibody Humanization: Modified CDR Grafting Methods
Table 16.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 17.1 Survey Insights: Overview of Respondents
Table 17.2 Survey Insights: Designations and Seniority Levels
Table 17.3 Survey Insights: Antibody Discovery Stages
Table 17.4 Survey Insights: Antibody Discovery Methods
Table 17.5 Survey Insights: Type of Antibody Discovered
Table 17.6 Survey Insights: Location of Antibody Discovery Facility / Laboratory
Table 17.7 Survey Insights: Likely Current Market Size
Table 19.1 Approved Monoclonal Antibodies: Development Trend Analysis
Table 19.2 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Table 19.3 Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
Table 19.4 Antibody Discovery Service Providers: Distribution by Antibody Discovery Methods
Table 19.5 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 19.6 Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered
Table 19.7 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 19.8 Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
Table 19.9 Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered
Table 19.10 Antibody Discovery Platform Providers: Distribution by Animal Model Used
Table 19.11 Antibody Discovery Service and Platform Providers: Geographical Distribution
Table 19.12 Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
Table 19.13 Abzena: Annual Revenues, 2013-H1 2018 (EUR Million)
Table 19.14 WuXi AppTec: Annual Revenues, 2012-Q1 2018 (USD Million)
Table 19.15 Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2018 (USD Million)
Table 19.16 Partnerships and Collaborations: Distribution by Number of Partnerships, 2011-2018
Table 19.17 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2018
Table 19.18 Partnerships and Collaborations: Year-Wise Distribution by Type of Collaboration
Table 19.19 Partnerships and Collaborations: Distribution by Type of Partnership Among Platform and Service Providers
Table 19.20 Partnerships and Collaborations: Leading Players by Number of Partnerships
Table 19.21 Partnerships and Collaborations: Distribution by Key Focus Areas
Table 19.22 Partnerships and Collaborations: Novel Antibody Types (2017-2018)
Table 19.23 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018
Table 19.24 Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
Table 19.25 Funding and Investment Analysis: Distribution of Amount Invested by Year, 2009-2018 (USD Million)
Table 19.26 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Table 19.27 Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018
Table 19.28 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Table 19.29 Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
Table 19.30 Funding and Investment Analysis: Most Active Players
Table 19.31 Funding and Investment Analysis: Most Active Investors
Table 19.32 Antibody Discovery Services Market, 2018-2030: Conservative Scenario (USD Billion)
Table 19.33 Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
Table 19.34 Antibody Discovery Services Market, 2018-2030: Optimistic Scenario (USD
Billion)
Table 19.35 Antibody Discovery Services Market, 2018 and 2030: Distribution by Region (USD Billion)
Table 19.36 Antibody Discovery Services Market, 2018-2030: North America, Conservative Scenario (USD Billion)
Table 19.37 Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
Table 19.38 Antibody Discovery Services Market, 2018-2030: North America, Optimistic Scenario (USD Billion)
Table 19.39 Antibody Discovery Services Market, 2018-2030: Europe, Conservative Scenario (USD Billion)
Table 19.40 Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
Table 19.41 Antibody Discovery Services Market, 2018-2030: Europe, Optimistic Scenario (USD Billion)
Table 19.42 Antibody Discovery Services Market, 2018-2030: China, Conservative Scenario (USD Billion)
Table 19.43 Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion)
Table 19.44 Antibody Discovery Services Market, 2018-2030: China, Optimistic Scenario (USD Billion)
Table 19.45 Antibody Discovery Services Market, 2018-2030: Rest of the World, Conservative Scenario (USD Billion)
Table 19.46 Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
Table 19.47 Antibody Discovery Services Market, 2018-2030: Rest of the World, Optimistic Scenario (USD Billion)
Table 19.48 Antibody Discovery Services: Market Attractiveness Analysis by Region
Table 19.49 Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Conservative Scenario (USD Billion)
Table 19. 50 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Base Scenario (USD Billion)
Table 19.51 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Optimistic Scenario (USD Billion)
Table 19.52 Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods (USD Billion)
Table 19.53 Antibody Discovery Services Market, 2018-2028: Distribution by Antibody Discovery Methods, Conservative Scenario (USD Billion)
Table 19.54 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Table 19.55 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Optimistic Scenario (USD Billion)
Table 19.56 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Table 19.57 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated (USD Billion)
Table 19.58 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Conservative Scenario (USD Billion)
Table 19.59 Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Table 19.60 Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Optimistic Scenario (USD Billion)
Table 19.61 Antibody Discovery Platforms Market, 2018 and 2030: Number of Licensing Deals 2018 and 2030 (USD Billion)
Table 19.62 Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030
Table 19.63 Antibody Discovery Platform Providers: Number of Licensing Deals, 2011- 2017
Table 19.64 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Table 19.65 Survey Insights: Distribution by Designation and Seniority Level
Table 19.66 Survey Insights: Distribution by Antibody Discovery Stages
Table 19.67 Survey Insights: Distribution by Antibody Discovery Methods
Table 19.68 Survey Insights: Distribution by Type Antibody Discovered
Table 19.69 Survey Insights: Location of Antibody Discovery Facility / Laboratory
Table 19.70 Survey Insights: Likely Current Market Size

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report